GOTHENBURG, Sweden, March 31, 2026 /PRNewswire/ -- Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare ...

Pulmonary arterial hypertension, or PAH, is a rare and severe disease characterized by elevated blood pressure in the pulmonary arteries, which transport blood from the heart to the lungs. This can ...

United Therapeutics has linked a once-daily drug candidate to a 55% drop in the risk of clinical worsening in a phase 3 trial, setting the company up to seek FDA approval in pulmonary arterial ...

A prespecified subgroup analysis showed that patients with intermediate and high-risk pulmonary arterial hypertension achieved significant improvements in walk distance and several secondary endpoints ...

Ah-Shi-Sle-Pah (gray salt in Navajo) is an official Bureau of Land Management wilderness area that has incredible land formations that will knock your socks off. It’s a little beyond the turnoff for ...

The mural called “Pah-Pah-Pah-Pah, Jya-Jyan!” would go up at the All Saints Episcopal Church at 555 Waverley St. Courtesy city of Palo Alto Downtown Palo Alto will soon get an infusion of color and ...

Please provide your email address to receive an email when new articles are posted on . Pulmonary arterial hypertension is more prevalent in women. Teratogenic medications and risks of pregnancy are ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use ...

Merck Receives Positive EU CHMP Opinion for Expanded Use of WINREVAIR™ (sotatercept) in Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1 Pulmonary Hypertension) Merck (NYSE: MRK), known ...

(StatePoint) November is Pulmonary Hypertension Awareness Month, and the American Lung Association, with support from Merck, is raising awareness about one form of the condition: pulmonary arterial ...

Adding WINREVAIR to background PAH therapy improved exercise capacity and WHO functional class (FC), and reduced the risk of clinical worsening events, including hospitalization for PAH, lung ...